[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335202-105":59,"doc-detail-335202-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","research-brief-a-next-generation-braf-inhibitor-overcomes-resistance-to-braf-inhibition-in-patients-with-braf-mutant-cancers-using-pharmacokinetics-informed-dose-escalation","ReseaRch BRief - A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation","","Research brief describing PF-07799933 (ARRY-440), a brain-penetrant selective pan-mutant BRAF inhibitor, and its ability to overcome resistance mechanisms limiting current RAF therapies. The study reports preclinical activity including disruption of endogenous mutant BRAF:wild-type CRAF dimers and sparing of wild-type ERK signaling. A first-in-human trial uses pharmacokinetics-informed dose escalation to rapidly reach efficacious exposures, enabling confirmed systemic and brain responses with manageable tolerability and combination feasibility with binimetinib.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/research-brief-a-next-generation-braf-inhibitor-overcomes-resistance-to-braf-inhibition-in-patients-with-braf-mutant-cancers-using-pharmacokinetics-informed-dose-escalation/335202/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/research-brief-a-next-generation-braf-inhibitor-overcomes-resistance-to-braf-inhibition-in-patients-with-braf-mutant-cancers-using-pharmacokinetics-informed-dose-escalation/335202.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does PF-07799933 aim to address in BRAF-mutant cancers?","Question",{"text":112,"@type":113},"PF-07799933 targets resistance-related pathway reactivation and limited brain penetration seen with approved RAF inhibitors, including mechanisms involving ERK signaling and RAF dimer formation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does PF-07799933 behave in preclinical experiments regarding signaling?",{"text":117,"@type":113},"PF-07799933 inhibits relevant signaling in vitro, disrupts endogenous mutant-BRAF:wild-type-CRAF dimers, and spares wild-type ERK signaling.",{"name":119,"@type":110,"acceptedAnswer":120},"What design feature enabled rapid achievement of efficacious drug exposure in the trial?",{"text":121,"@type":113},"The first-in-human study used a novel, flexible pharmacokinetics-informed dose escalation design to reach PF-07799933 efficacious concentrations quickly.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335202,1790142743,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","ReseaRch BRief  \nA Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation   \nRona Yaeger1, Meredith A. McKean2, Rizwan Haq3, J. Thaddeus Beck4, Matthew H. Taylor5, Jonathan E. Cohen6, Daniel W. Bowles7, Shirish M. Gadgeel8, Catalin Mihalcioiu9, Kyriakos P. Papadopoulos10, Eli L. Diamond1,  \nKeren B. Sturtz11, Gang Feng12, Stefanie K. Drescher11, Micaela B. Reddy11, Bhaswati Sengupta11, Arnab K. Maity12, Suzy A. Brown11, Anurag Singh11, Eric N. Brown11, Brian R. Baer11, Jim Wong11, Tung-Chung Mou11, Wen-I Wu11, Dean R. Kahn11, Sunyana Gadal1, Neal Rosen1, John J. Gaudino11, Patrice A. Lee11, Dylan P. Hartley11, and S. Michael Rothenberg11, 13  \nRAF inhibitors have transformed treatment for patients with BRAFV600-mutant can  \ncers, but clinical benefit is limited by adaptive induction of ERK signaling, genetic alterations that induce BRAFV600 dimerization, and poor brain penetration. Next-generation pan-RAF dimer inhibitors are limited by a narrow therapeutic index. PF-07799933 (ARRY-440) is a brain-penetrant, selective, pan-mutant BRAF inhibitor. PF-07799933 inhibited signaling in vitro, disrupted endogenous mutant-BRAF:wild-type-CRAF dimers, and spared wild-type ERK signaling. PF-07799933 ± binimetinib inhibited growth of mouse xenograft tumors driven by mutant BRAF that functions as dimers and by BRAFV600E with acquired resistance to current RAF inhibitors. We treated patients with treatmentrefractory BRAF-mutant solid tumors in a first-in-human clinical trial (NCT05355701) that utilized a novel, flexible, pharmacokinetics-informed dose escalation design that allowed rapid achievement of PF-07799933 efficacious concentrations. PF-07799933 ± binimetinib was well-tolerated and resulted in multiple confirmed responses, systemically and in the brain, in patients with BRAF-mutant cancer who were refractory to approved RAF inhibitors.  \nSIGNIFICANCE: PF-07799933 treatment was associated with antitumor activity against BRAFV600-and non-V600-mutant cancers preclinically and in treatment-refractory patients, and PF-07799933 could be safely combined with a MEK inhibitor. The novel, rapid pharmacokinetics (PK)-informed dose escalation design provides a new paradigm for accelerating the testing of next-generation targeted therapies early in clinical development.  \n1Memorial Sloan Kettering Cancer Center, New York, New York. 2Sarah Cannon Research Institute, Nashville, Tennessee. 3Dana Farber Cancer Institute, Boston, Massachusetts. 4Highlands Oncology, Fayetteville, Arkansas.  \n5Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon. 6Hadassah Medical Center, Jerusalem, Israel. 7University of Colorado Hospital, Aurora, Colorado. 8Henry Ford Health System, Detroit, Michigan.  \n9McGill University Health Centre, Montreal, Canada. 10South Texas Accelerated Research Therapeutics, San Antonio, Texas. 11Pfizer Boulder Research and Development, Boulder, Colorado. 12Pfizer Early Clinical Development, Cambridge, Massachusetts. 13Pfizer Oncology Research and Development, La Jolla, California.  \nCorresponding Authors: Rona Yaeger, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065. E-mail: [yaegerr@mskcc.org](yaegerr@mskcc.org); and S.M. Rothenberg, insitro inc., South San Francisco,  \nCA 94080. E-mail: [smichael@insitro. com](smichael@insitro. com)  \nCancer Discov 2024;14:1599–611  \ndoi: 10. 1158/2159-8290 . CD-24-0024  \nThis open access article is distributed under the Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.  \n©2024 The Authors; Published by the American Association for Cancer Research  \ninTRoducTion  \nOncogenicBRAF mutant protein monomers are categorized into Class I (monomers), II (Ras-independent, constitutively activated dimers), and III (Ras-dependent, hypoactive dimers) based on their activities as monomers or homo/heterodim","cbCairpVNRRltUHH","https://ap.wps.com/l/cbCairpVNRRltUHH","pdf",10752223,13,"English","# Background and Rationale\n## Limitations of current RAF inhibition\n# PF-07799933 Preclinical Findings\n## Targeting dimers and ERK pathway effects\n# First-in-Human Clinical Trial Results\n## PK-informed dose escalation design\n## Safety and confirmed responses\n# Significance and Future Implications","[{\"question\":\"What problem does PF-07799933 aim to address in BRAF-mutant cancers?\",\"answer\":\"PF-07799933 targets resistance-related pathway reactivation and limited brain penetration seen with approved RAF inhibitors, including mechanisms involving ERK signaling and RAF dimer formation.\"},{\"question\":\"How does PF-07799933 behave in preclinical experiments regarding signaling?\",\"answer\":\"PF-07799933 inhibits relevant signaling in vitro, disrupts endogenous mutant-BRAF:wild-type-CRAF dimers, and spares wild-type ERK signaling.\"},{\"question\":\"What design feature enabled rapid achievement of efficacious drug exposure in the trial?\",\"answer\":\"The first-in-human study used a novel, flexible pharmacokinetics-informed dose escalation design to reach PF-07799933 efficacious concentrations quickly.\"}]","ReseaRch BRief - A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation | PDF",1790010120,33]